Most studies found that METTL3, an oncogene, was upregulated in RCC compared to normal tissues and correlated with poor outcomes (Zhang et al., 2020a; Chen et al., 2020b; Wang et al., 2020c; Zhao et al., 2020). Here, METTL3 is linked to renal cell adenocarcinoma.